• Explore /
  • Poster
  • / Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia.

Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia.

Abstract Video & Slides Poster

Authors

Edward Li

Edward C. Li

Sandoz Inc, Princeton, NJ

Edward C. Li, Kimberley J. Campbell, Bridgette Kanz Schroader, David Campbell, Stephen Chaplin, Gary H. Lyman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cost, Value, and Policy; Health Equity and Disparities; Patient Experience

Track

Cost, Value, and Policy,Technology and Innovation in Quality of Care,Health Care Access, Equity, and Disparities,Patient Experience,Quality, Safety, and Implementation Science

Sub Track

Value/Cost of Care

Citation

J Clin Oncol 39, 2021 (suppl 28; abstr 58)

DOI

10.1200/JCO.2020.39.28_suppl.58

Abstract #

58

Poster Bd #

C1

Abstract Disclosures

Similar Posters

First Author: Gary H. Lyman

First Author: Jaime Shaw

First Author: Edward C. Li

First Author: Meena Okera